Kailera Therapeutics CPO reports option holdings
Kailera Therapeutics, Inc. reported the initial equity holdings of Chief People Officer Paula Cloghessy on a Form 3, showing multiple stock option awards to purchase common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Kailera Therapeutics, Inc. reported the initial equity holdings of Chief People Officer Paula Cloghessy on a Form 3, showing multiple stock option awards to purchase common stock. These options give her the right to buy shares at exercise prices between $5.25 and $7.24 per share.
The holdings include options over 230,728 underlying shares at an exercise price of $7.24 expiring in 2035, 95,350 shares at $5.40 expiring in 2035, and two grants of 86,150 and 128,388 shares at $5.25 expiring in 2034. Footnotes state each grant vests 25% on specified initial vesting dates in 2025 or 2026, then in 36 substantially equal monthly installments, subject to her continued service.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Cloghessy Paula
Role
Chief People Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 540,616 contracts (Direct)
Footnotes (4)
- F1. The options vested and became exercisable as to 25% of the total shares on June 17, 2025 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
- F2. The options vested and became exercisable as to 25% of the total shares on December 9, 2025 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
- F3. The options vested and became exercisable as to 25% of the total shares on February 27, 2026 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
- F4. The options vest and become exercisable as to 25% of the total shares on November 5, 2026 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Option grant 1 exercise price: $7.24 per share
Option grant 1 underlying shares: 230,728 shares
Option grant 2 exercise price: $5.40 per share
+3 more
6 metrics
Option grant 1 exercise price
$7.24 per share
Stock Option (right to buy), expiration November 5, 2035
Option grant 1 underlying shares
230,728 shares
Common Stock underlying, direct ownership
Option grant 2 exercise price
$5.40 per share
Stock Option (right to buy), expiration February 27, 2035
Option grant 2 underlying shares
95,350 shares
Common Stock underlying, direct ownership
Option grant 3 underlying shares
86,150 shares
Exercise price $5.25, expiration December 9, 2034
Option grant 4 underlying shares
128,388 shares
Exercise price $5.25, expiration September 19, 2034
Key Terms
Stock Option (right to buy), underlying security title, exercise price, vesting, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
underlying security title financial
"underlying_security_title: Common Stock"
exercise price financial
"conversion_or_exercise_price: 7.2400"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The options vested and became exercisable as to 25% of the total shares"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
monthly installments financial
"thereafter in 36 substantially equal monthly installments"
Monthly installments are regular, fixed payments made each month to gradually pay off a larger amount, such as a loan or purchase. Think of it like paying for a big item in small, manageable parts instead of all at once. For investors, understanding installment payments helps gauge how debts are structured and how they might affect financial stability or cash flow over time.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Kailera Therapeutics (KLRA) disclose in Paula Cloghessy’s Form 3?
Kailera Therapeutics discloses Chief People Officer Paula Cloghessy’s existing stock option holdings. The filing lists several grants to purchase common stock, including exercise prices, expiration dates, and vesting schedules tied to continued service with the company over multi-year periods.
How many stock option grants does Paula Cloghessy hold at Kailera Therapeutics (KLRA)?
The Form 3 lists four separate stock option awards. Each award is a “Stock Option (right to buy)” common stock, with different exercise prices, expiration dates, and underlying share amounts, reflecting multiple equity grants received as part of her compensation as Chief People Officer.
What are the exercise prices of Paula Cloghessy’s options at Kailera Therapeutics (KLRA)?
Her reported options have exercise prices of $7.24, $5.40, and $5.25 per share. These prices represent the cost per share she must pay to purchase Kailera Therapeutics common stock if she exercises each respective stock option grant in the future.
When do Paula Cloghessy’s stock options at Kailera Therapeutics (KLRA) start vesting?
Footnotes state that different grants began vesting 25% on June 17, 2025, December 9, 2025, and February 27, 2026. Another grant will vest 25% on November 5, 2026. Remaining portions vest in 36 substantially equal monthly installments, contingent on continued service.
What are the expiration dates of the Kailera Therapeutics (KLRA) options held by Paula Cloghessy?
The Form 3 shows expiration dates in 2034 and 2035. Specifically, certain options expire on September 19, 2034 and December 9, 2034, while others expire on February 27, 2035 and November 5, 2035, defining the latest dates she can exercise each grant.
Does Paula Cloghessy’s Form 3 for Kailera Therapeutics (KLRA) show any recent buy or sell transactions?
The Form 3 primarily reports holdings rather than new trades. Transactions are categorized as holdings with unknown transaction codes, and the transaction summary shows no buy, sell, or option exercise counts, indicating this filing is an initial ownership report, not a record of recent trading.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates